BCMA CAR-T cells

Phase 2Cell therapy

CChongqing Precision Biotech Co., Ltd

BCMA CAR-T cells is one of 43 biologic programs targeting Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaUnknown status

MyelomaRecruiting

Multiple MyelomaPhase 2

Unknown status

MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Fludara

Sanofi

Phase 3

47 3

Venclexta

AbbVie

Phase 3

17 4

Keytruda

Merck & Co.

Phase 3

17 5

Opdivo

Bristol-Myers Squibb

Phase 3

11 6

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 7

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

22 8

Treanda

AAzurity Pharmaceuticals

Phase 3

19 9

Neulasta

Amgen

Phase 3

5 10

Elranatamab

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Multiple Myeloma

NCT04776330

Phase 1/2Recruiting

Multiple Myeloma

NCT04271644

Q1 2029

Phase 1Recruiting

Myeloma

NCT04795882

Clinical

Trials by Indication[1]

Multiple Myeloma7 trials

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Unknown status·SShenzhen University General Hospital·Phase 1/2·NCT05150522·10 enrolled

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04776330·80 enrolled

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Unknown status·ZZhejiang University·Phase 2·NCT05712083·40 enrolled

Show 4 more trials

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04271644·80 enrolled

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Unknown status·ZZhejiang University·Phase 1·NCT05740891·50 enrolled

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma

Unknown status·TThe Pregene (ShenZhen) Biotechnology Company, Ltd.·Phase 1·NCT03661554·15 enrolled

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04272151·40 enrolled

Myeloma1 trial

A New Study Evaluating the Activity of Modular CAR T for mYeloma

Recruiting·UUniversity College, London·Phase 1·NCT04795882·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for BCMA CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCMA CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCMA CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: CChongqing Precision Biotech Co., Ltd

BCMA CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2029

Trials by Indication[1]

Multiple Myeloma7 trials

Myeloma1 trial

References

Drug Info

Quick Facts

Related News